
BTIG initiated coverage on Bright Minds Biosciences Inc. (NASDAQ:DRUG), a clinical-stage company focused on neurological and psychiatric disorders.
Investment in Bright Minds is based on the expectation that BMB-101 will effectively and precisely treat absence seizures without unacceptable toxicities.